NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
Rhea-AI Summary
NeuroSense (NASDAQ:NRSN) received South Korean Patent No. 10-2969898 covering the composition of PrimeC, its lead ALS candidate. The patent protects formulation, manufacturing process, pharmacokinetics and ALS use in South Korea through 2042.
This grant follows patents in Japan, Brazil, Australia and the US and supports plans to initiate the pivotal Phase 3 PARAGON ALS study, after Phase 2b PARADIGM results that, according to NeuroSense, showed slowed disease progression, biomarker activity and survival benefit.
Positive
- South Korean patent protection for PrimeC composition and use expected through 2042
- Patent covers formulation, manufacturing process, pharmacokinetics and ALS pharmaceutical use
- Follows PrimeC patent grants in Japan, Brazil, Australia and the United States
- Global intellectual property portfolio supports long-term PrimeC development and commercialization strategy
- FDA clearance obtained to initiate pivotal Phase 3 PARAGON ALS study
- Phase 2b PARADIGM data reportedly showed slowed ALS progression, biomarker activity and survival benefit
Negative
- None.
News Market Reaction – NRSN
In the Jun 11 session, NRSN gained 1.05%, reflecting a mild positive market reaction. Argus tracked a peak move of +6.5% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 09 | Japanese patent grant | Positive | -0.2% | Japan patent extended PrimeC composition protection and reinforced global IP strategy. |
| Apr 28 | Insider PIPE financing | Positive | +7.8% | Insider-led $600,000 private placement at premium pricing to support upcoming milestones. |
| Apr 06 | Brazil patent grant | Positive | -8.2% | Brazilian patent to October 2042 strengthened PrimeC’s IP after U.S. and Australia grants. |
| Mar 31 | Year-end results | Negative | +3.3% | 2025 results showed $0.2M cash and $11.125M net loss despite advancing PrimeC program. |
| Mar 24 | Regulatory update | Positive | -1.5% | Regulatory milestones and upcoming Alzheimer’s readout highlighted alongside prior survival data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive patents and clinical updates often saw muted or negative next-day moves, while financing and mixed earnings produced the only notable positive reaction.
Over the last months, NRSN has steadily expanded PrimeC’s IP, with recent patents in Japan, Brazil, and now South Korea extending protection toward 2042. These came alongside FDA clearance to start the pivotal Phase 3 PARAGON ALS trial and strong Phase 2b PARADIGM data, including survival benefits. Despite this, prior patent and regulatory updates on Mar 24, Apr 6, and
Key Terms
pharmacokinetic medical
biomarkers medical
micrornas medical
amyotrophic lateral sclerosis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS
- Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in
Japan ,Brazil ,Australia andthe United States - Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC
The granted patent claims cover key aspects of PrimeC, including its proprietary tablet formulation, manufacturing process, pharmacokinetic characteristics, and pharmaceutical use for the treatment of ALS.
The patent is expected to provide patent protection for such aspects of PrimeC in
"This patent grant further strengthens our growing global intellectual property estate surrounding PrimeC," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "
The South Korean patent grant follows patent grants received in other major jurisdictions, further expanding NeuroSense's global intellectual property portfolio and supporting the long-term development and commercialization strategy for PrimeC.
PrimeC is a novel oral therapy designed to simultaneously target multiple biological mechanisms associated with ALS progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
NeuroSense previously reported compelling results from its Phase 2b PARADIGM study, including meaningful slowing of disease progression, significant biological activity across multiple ALS-related biomarkers, including microRNAs, and long-term data demonstrating a meaningful survival benefit. The Company has received clearance from the
About NeuroSense
NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC's multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS.
NeuroSense has received clearance from the
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.
About ALS
Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements, including statements regarding the benefits of the Korean patent, development, regulatory progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the benefits of the Korean patent; outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurosense-granted-south-korean-patent-covering-primec-composition-for-als-302797996.html
SOURCE NeuroSense